Logo
x

Search

Subscribe Now

First Therapy

Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyroid Cancers

Eli Lilly's Retevmo (selpercatinib) Receives the US FDA's Approval as the First Therapy to Treat Advanced RET-Driven Lung and Thyr...

  • May 11, 2020
AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas

AstraZeneca and MSD's Koselugo (selumetinib) Receives the US FDA's Approval as the First Therapy for Pediatric Patients with Neuro...

  • April 13, 2020
Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

  • March 6, 2020
Pfizer's Vyndaqel (tafamidis- 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in the EU

Pfizer's Vyndaqel (tafamidis- 61mg) Receives EC's Approval as the First Therapy to Treat Transthyretin Amyloid Cardiomyopathy in t...

  • February 18, 2020
Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

  • January 24, 2020
Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

  • January 22, 2020
Boehringer Ingelheim

    Boehringer Ingelheim's Ofev (nintedanib) Receives Health Canada's Approval as the First Therapy to Treat SSc-ILD in Canada

    • November 28, 2019
    Alnylam

      Alnylam's Givlaari (givosiran) Receives the US FDA's Approval as the First Therapy for Acute Hepatic Porphyria

      • November 21, 2019
      Celgene

        Celgene's Reblozyl (luspatercept–aamt) Receives FDA's Approval as the First Therapy to Treat Patients with Rare Blood Disorder

        • November 11, 2019
        Lilly

          Lilly's Reyvow (lasmiditan) Receives FDA's Approval as the First Therapy in a New Class of Acute Treatment for Migraine

          • October 14, 2019
          Image

          Incisive News in 3 Shots.

          Contact Us

          Our Information

          Follow Us

          Copyright © 2025 PharmaShots - All Rights Reserved.